Brook I
Naval Medical Research Institute, Bethesda, Maryland 20814-5055.
Antimicrob Agents Chemother. 1993 Jul;37(7):1531-5. doi: 10.1128/AAC.37.7.1531.
Cefoxitin, cefotetan, and cefmetazole were compared in 10-day therapy of intra-abdominal and subcutaneous infections caused by three organisms: Bacteroides fragilis and Bacteroides thetaiotaomicron combined with either Escherichia coli or Staphylococcus aureus. Intra-abdominal infection was caused by B. fragilis plus B. thetaiotaomicron plus E. coli. Therapy was initiated immediately before inoculation or was delayed for 8 h. Mortality was 14 of 30 (47%) for saline-treated mice, and all survivors developed abscesses. Immediate therapy reduced mortality and the percentage of mice with abscesses (in survivors), respectively, to 17 and 20% with cefoxitin, 0 and 13% with cefotetan, and 0 and 17% with cefmetazole, and the numbers of all bacteria were reduced by all the cephalosporins. Delayed therapy reduced mortality and abscess formation, respectively, to 20 and 8% of mice with cefoxitin, 10 and 93% with cefotetan, and 7 and 96% with cefmetazole. B. thetaiotaomicron survived in all abscesses treated with cefotetan and cefmetazole. Subcutaneous abscesses were caused by each organism alone or in combinations of one aerobe (S. aureus or E. coli) and one or two Bacteroides species. Early therapy reduced the numbers of all bacteria independent of their in vitro susceptibility. All agents reduced the number of each Bacteroides species with either E. coli or S. aureus. However, when therapy was delayed, cefotetan and cefmetazole were less effective than cefoxitin against B. thetaiotaomicron. Cefotetan was the most active agent against E. coli, and cefmetazole was the most effective against S. aureus. These data illustrate the efficacy of all tested cephalosporins in the prophylaxis of polymicrobial infections.
对头孢西丁、头孢替坦和头孢美唑进行了比较,用于治疗由三种微生物引起的腹腔内和皮下感染,疗程为10天。这三种微生物分别是脆弱拟杆菌、解没食子酸拟杆菌,它们与大肠埃希菌或金黄色葡萄球菌联合感染。腹腔内感染由脆弱拟杆菌、解没食子酸拟杆菌和大肠埃希菌引起。治疗在接种前立即开始,或延迟8小时开始。用生理盐水处理的小鼠中,30只中有14只(47%)死亡,所有存活小鼠均出现脓肿。立即治疗使死亡率以及存活小鼠中出现脓肿的百分比分别降低:使用头孢西丁时降至17%和20%,使用头孢替坦时降至0和13%,使用头孢美唑时降至0和17%,并且所有头孢菌素都能减少所有细菌的数量。延迟治疗使死亡率和脓肿形成率分别降低:使用头孢西丁时降至20%和8%,使用头孢替坦时降至10%和93%,使用头孢美唑时降至7%和96%。在用头孢替坦和头孢美唑治疗的所有脓肿中,解没食子酸拟杆菌均存活。皮下脓肿由每种微生物单独引起,或由一种需氧菌(金黄色葡萄球菌或大肠埃希菌)与一种或两种拟杆菌属物种组合引起。早期治疗可减少所有细菌的数量,与它们在体外的敏感性无关。所有药物都能减少与大肠埃希菌或金黄色葡萄球菌共同感染时每种拟杆菌属物种的数量。然而,当治疗延迟时,头孢替坦和头孢美唑对解没食子酸拟杆菌的疗效不如头孢西丁。头孢替坦对大肠埃希菌最具活性,头孢美唑对金黄色葡萄球菌最有效。这些数据说明了所有受试头孢菌素在预防多微生物感染方面的疗效。